[Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing].
Carlsson
Per
P
Centrum för medicinsk teknologi, CMT, Linköpings universitet. Per.Carlsson@ihs.lius.se
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003657:Decision Making; D016527:Drug Costs; D005102:Health Expenditures; D006292:Health Priorities / Q000191:economics; D006801:Humans; D007348:Insurance, Health / Q000191:economics; D017410:Practice Guidelines as Topic; D013548:Sweden